Solid Biosciences (SLDB) Accounts Payables (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Accounts Payables data on file, last reported at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 13.6% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $5.6 million (down 13.6% YoY), and the FY2025 full-year result was $3.2 million, down 23.91% from the prior year.
• Accounts Payables rose to $5.6 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.4 million in Q3 2025 to a low of $1.7 million in Q1 2024.
• A 5-year average of $4.2 million and a median of $4.2 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables plunged 69.08% in 2024 and surged 272.2% in 2025, its largest moves.
• Tracing SLDB's Accounts Payables over 5 years: stood at $3.2 million in 2022, then sank by 37.25% to $2.0 million in 2023, then soared by 108.51% to $4.2 million in 2024, then decreased by 23.91% to $3.2 million in 2025, then jumped by 72.55% to $5.6 million in 2026.
• Business Quant data shows SLDB's Accounts Payables at $5.6 million in Q1 2026, $3.2 million in Q4 2025, and $8.4 million in Q3 2025.